Use of the Probiotic Limosilactobacillus reuteri as an Adjunct to Subgingival Instrumentation in the Treatment of Periodontitis Patients With Diabetes: A Randomised Clinical Trial.
- 2025-09-17
- RCT · n = 40
- Journal of clinical periodontology 53(1)
- Rocío Bujaldón
- Eduardo Montero
- Juan Daniel Gamonal
- Alejandro Abuelo
- María José Marín
- Margarita Iniesta
- Mariano Sanz
- David Herrera
- PubMed: 40958659
- DOI: 10.1111/jcpe.70035
- High evidence
- Clinical
At 6 months, both groups showed statistically significant reductions in the primary outcome (mean probing depth), with reductions of 0.9 mm in the probiotic group and 0.8 mm in the placebo group, with no significant differences between them.
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- tablets containing L. reuteri for 3 months (exact dose not specified in abstract)